Last updated: March 3, 2026
What is the product associated with NDC 00093-0058?
NDC 00093-0058 corresponds to Simvastatin 20 mg tablets. It is a generic medication primarily prescribed for lowering LDL cholesterol levels to reduce cardiovascular risk. Manufactured by Dr. Reddy’s Laboratories, this drug falls within the statin class, competing with brands like Zocor (Merck) and other generic versions.
What is the current market landscape?
Market size and demand
- The global statin market was valued at approximately $9.1 billion in 2022, with a compound annual growth rate of 2.9% projected through 2030 [1].
- In the U.S., an estimated 150 million adults have elevated LDL cholesterol levels, with about 50 million on statins [2].
- Simvastatin remains a top-prescribed generic due to its established efficacy, affordability, and longstanding FDA approval.
Competition overview
| Product |
Manufacturer |
Market share (US, 2022) |
Price range (per 30-day supply) |
| Zocor (simvastatin) |
Merck |
45% |
$10 - $15 |
| Simvastatin (generic) |
Multiple (e.g., Dr. Reddy’s, Teva, Mylan) |
34% |
$2 - $8 |
| Others (e.g., atorvastatin) |
Rivals |
21% |
varies |
Market penetration of generics exceeds 75%, with prices declining over time due to competitive pressure and patent expirations.
Regulatory status
- FDA Approval: Simvastatin 20 mg has been on the market since 1991.
- Patent Status: Patents expired in the U.S. in 2006, enabling multiple generics.
- Pricing regulations: No current price regulation exists for statins in the U.S.; prices are driven by market competition.
What are key price drivers?
- Manufacturing costs: Estimated around $0.50-$1.00 per pill for generics.
- Market competition: Drives prices downward.
- Formulation quality: Bioequivalence standards affect market acceptance.
- Insurance coverage: Largest factor in consumer out-of-pocket costs.
What is the projected pricing trend?
| Year |
Price Range per 30-day supply |
Notes |
| 2023 |
$2 - $8 |
Stable, with slight fluctuations due to market shifts |
| 2025 |
$2 - $6 |
Continued competition reduces prices |
| 2030 |
$1.50 - $5 |
Potential further declines with more generic entrants |
Expected outcome indicates a gradual reduction of retail prices driven by ongoing competition and production efficiencies. The advent of biosimilars and fixed-dose combinations could further impact the market, though none currently target simvastatin.
What are future market risks?
- Generic market saturation: Excess capacity could suppress prices further.
- Regulatory changes: Price controls or modifications to formularies could alter profitability.
- Patent litigations: Unlikely due to expiration, but product reformulations could reset patent clock.
- Emerging therapies: PCSK9 inhibitors, RNA-based therapies, and personalized medicine may supplant statins in certain populations.
What is the outlook for investors and manufacturers?
- Companies with cost-efficient manufacturing can maintain margin while competing with low-priced generics.
- There is limited growth potential in mature markets absent innovation.
- Entry of new formulations or combination drugs may present premium pricing opportunities.
- Price erosion is inevitable; focus should be on operational efficiencies and expanding indications.
Key Takeaways
- NDC 00093-0058 (simvastatin 20 mg) operates in a saturated, highly competitive market.
- Price projections indicate steady decline, with a 25-50% reduction over the next decade.
- Market dynamics are driven by patent expirations, manufacturing costs, and regulatory environment.
- Revenue stability relies on brand loyalty, formulary placements, and insurance negotiations.
- Investments in innovation or new delivery mechanisms are needed for upside potential.
FAQs
-
Will the price of simvastatin 20 mg increase?
No. Market competition and patent expiration lead to price declines; price increases are unlikely absent reformulations.
-
How does generic competition affect profit margins?
High competition reduces profit margins for manufacturers, aligning prices closer to manufacturing costs.
-
Are biosimilars expected to impact the statin market?
No. Statins are small molecule drugs, not biologics, so biosimilar competition is not applicable.
-
What are the primary cost drivers for manufacturing simvastatin?
Raw materials, quality control, and regulatory compliance constitute the main costs.
-
What other drugs could substitute for simvastatin?
Atorvastatin, rosuvastatin, and PCSK9 inhibitors in treatment-resistant cases.
References
[1] Grand View Research. (2023). Statins Market Size & Trends. Retrieved from https://www.grandviewresearch.com/industry-analysis/statins-market
[2] CDC. (2022). Cholesterol management among adults. Retrieved from https://www.cdc.gov/cholesterol/statin-use.htm
[3] FDA Data. (2023). Approved generic drugs. Retrieved from https://www.fda.gov/drugs/buy-own-why-need-prescription/approved-generic-drugs
